Related Experiment Video
Updated: Jun 4, 2026
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Association between Staphylococcus aureus colonization and clinical improvement in pediatric atopic dermatitis
Cristiana Indolfi1, Angela Klain1, Giulio Dinardo1
1Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli, Naples, Italy.
Insights
Dupilumab significantly improves moderate-to-severe atopic dermatitis (AD) in children, reducing symptoms and improving quality of life. The treatment also correlates with decreased Staphylococcus aureus colonization in pediatric AD patients.
Area of Science:
- Pediatric Dermatology
- Immunology
- Microbiology
Background:
- Moderate-to-severe atopic dermatitis (AD) in children involves skin barrier dysfunction, inflammation, and frequent Staphylococcus aureus (S. aureus) colonization, worsening disease.
- Dupilumab, an anti-IL-4/IL-13 receptor antibody, shows promise for pediatric AD, but data on microbial changes are limited.
Purpose of the Study:
- To evaluate dupilumab's efficacy in children with moderate-to-severe AD unresponsive to standard treatments.
- To analyze skin and nasal microbial colonization patterns at 12 months in children treated with dupilumab, compared to those receiving conventional therapy and healthy controls.
Main Methods:
- A prospective observational study enrolled children aged 6-16 years into three groups: dupilumab treatment, conventional topical therapy, and healthy controls.
- Clinical outcomes (EASI, C-DLQI, NRS) and microbial colonization (nasal/skin swabs cultured and identified) were assessed over 12 months.
Main Results:
- Dupilumab treatment led to rapid and sustained improvements in C-DLQI, EASI, and pruritus scores within 3-12 months, with no adverse events.
- At 12 months, S. aureus nasal colonization was lower in the dupilumab group (2/10) compared to conventional therapy (4/10) and controls (1/10).
- Skin S. aureus was absent in dupilumab-treated patients, versus 8/10 in the conventional therapy group and 0/10 in controls.
Conclusions:
- Dupilumab offers sustained clinical benefits for pediatric atopic dermatitis.
- This pilot study suggests dupilumab is associated with reduced S. aureus colonization and increased commensal staphylococci in pediatric AD.
Background:
Moderate-to-severe atopic dermatitis (AD) in children is characterized by impaired skin barrier function, type 2 inflammation, and frequent Staphylococcus aureus colonization, contributing to disease severity and risk of superinfection. Dupilumab, an anti-IL-4/IL-13 receptor monoclonal antibody, improves clinical outcomes in pediatric AD, but longitudinal data on culture-based skin and nasal microbial changes remain limited.
Objective:
To assess dupilumab efficacy in children with moderate-to-severe AD unresponsive to conventional therapy and to describe skin and nasal microbial colonization patterns at the 12-month time point compared with moderate AD receiving conventional topical therapy and healthy controls.
Methods:
Prospective observational study. Children aged 6-16 years were enrolled in three groups: (a) moderate-to-severe AD starting dupilumab (assessments at baseline, 3, 6, and 12 months); (b) moderate AD receiving conventional topical therapy not eligible for biologic therapy; and (c) age-matched healthy controls. Outcomes included Eczema Area and Severity Index (EASI), Children's Dermatology Life Quality Index (C-DLQI), and Peak Pruritus Numerical Rating Scale (NRS). At 12 months, nasal and skin e-Swabs were cultured; isolates were identified by MALDI-TOF with antimicrobial susceptibility testing. Longitudinal changes were analyzed using the Friedman test (p < 0.05).
Results:
Ten dupilumab-treated children (mean age 13 years; 60% males) showed rapid and sustained improvement in C-DLQI (median 13.5 to 3 at 3 months; 3.5 at 12 months), EASI (24.5 to 5.65 at 3 months, 1.2 at 12 months), and pruritus (NRS 10 to 4.5 at 3 months; 5.5 at 12 months). No adverse events or discontinuations occurred. At 12 months, nasal S. aureus colonization was detected in 2/10 dupilumab-treated patients versus 4/10 moderate AD receiving conventional topical therapy and 1/10 controls; skin S. aureus was absent in dupilumab-treated patients but present in 8/10 children with moderate atopic dermatitis receiving conventional topical therapy and 0/10 controls.
Conclusion:
Dupilumab provides sustained clinical benefit and, in this cross-sectional assessment of a small pilot cohort, is associated with lower S. aureus colonization and the presence of commensal staphylococci in pediatric atopic dermatitis.
Related Concept Videos
01:29Staphylococcal Skin Infections
01:25Clinical Significance of Antibiotic Resistance